Immune Persistence and Safety After SARS-CoV-2 BNT162b1 mRNA Vaccination in Chinese Adults: A Randomized, Placebo-Controlled, Double-Blind Phase 1 Trial

por Li, Jingxin, Hui, Ai-Min, Zhang, Xiang, Ge, Lei, Qiu, Yuanzheng, Tang, Rong, Ye, Huayue, Wang, Xiyuan, Lin, Mei, Zhu, Zhongkui, Zheng, Jianfei, Qiu, Jingjun, Lagkadinou, Eleni, Shpyro, Svetlana, Ozhelvaci, Orkun, Türeci, Özlem, Khondker, Zakaria, Yin, Wanrong, Shishkova, Yoana, Jia, Siyue, Pan, Hongxing, Peng, Fuzhong, Ma, Zhilong, Wu, Zhenggang, Guo, Xiling, Shi, Yunfeng, Muik, Alexander, Şahin, Uğur, Zhu, Li, Zhu, Fengcai
Publicado 2022

Immunogenicity and safety of BNT162b2 mRNA vaccine in Chinese adults: A phase 2 randomised clinical trial

por Hui, Ai-Min, Li, Jingxin, Zhu, Li, Tang, Rong, Ye, Huayue, Lin, Mei, Ge, Lei, Wang, Xiyuan, Peng, Fuzhong, Wu, Zhenggang, Guo, Xiling, Shi, Yunfeng, Pan, Hongxing, Zhu, Jiahong, Song, Zhizhou, Qiu, Jingjun, Wang, Wei, Zheng, Jianfei, Ozhelvaci, Orkun, Shpyro, Svetlana, Bushway, Meghan, Derhovanessian, Evelyna, Kühnle, Marie-Cristine, Luxemburger, Ulrich, Muik, Alexander, Shishkova, Yoana, Khondker, Zakaria, Hu, Simin, Lagkadinou, Eleni, Şahin, Uğur, Türeci, Özlem, Zhu, Fengcai
Publicado 2022